Everence Capital Management Inc. Sells 22,620 Shares of Organon & Co. (NYSE:OGN)

Everence Capital Management Inc. decreased its holdings in shares of Organon & Co. (NYSE:OGN) by 65.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,050 shares of the company’s stock after selling 22,620 shares during the period. Everence Capital Management Inc.’s holdings in Organon & Co. were worth $180,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC increased its position in shares of Organon & Co. by 238.0% in the third quarter. Barclays PLC now owns 119,483 shares of the company’s stock valued at $2,285,000 after acquiring an additional 84,136 shares during the period. Public Sector Pension Investment Board raised its stake in Organon & Co. by 8.0% in the second quarter. Public Sector Pension Investment Board now owns 565,866 shares of the company’s stock worth $11,713,000 after buying an additional 41,954 shares in the last quarter. Weiss Asset Management LP purchased a new stake in Organon & Co. in the third quarter worth about $32,966,000. Cerity Partners LLC grew its holdings in shares of Organon & Co. by 94.0% during the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock worth $12,766,000 after acquiring an additional 323,308 shares during the period. Finally, Beddow Capital Management Inc. raised its position in shares of Organon & Co. by 38.8% in the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock worth $5,867,000 after acquiring an additional 85,775 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Trading Up 1.7 %

Organon & Co. stock opened at $15.99 on Friday. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The company has a market capitalization of $4.12 billion, a price-to-earnings ratio of 3.17, a price-to-earnings-growth ratio of 0.81 and a beta of 0.76. The business’s fifty day simple moving average is $15.41 and its two-hundred day simple moving average is $18.44. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the company posted $0.78 earnings per share. As a group, equities analysts predict that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.00%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Analysts Set New Price Targets

Separately, Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.